Mylan/Biocon biosimilar shows equivalence to Herceptin

Mylan Inc. (NASDAQ:MYL) and partner Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said Myl-1401O, their biosimilar of Herceptin trastuzumab, met the primary endpoint of bioequivalence to its reference product in the Phase

Read the full 294 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE